Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
基本信息
- 批准号:10557162
- 负责人:
- 金额:$ 36.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-01 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:AdenovirusesAdjuvantAgonistAntineoplastic AgentsAryl Hydrocarbon ReceptorAttenuatedBiologicalBiological ProductsBrain NeoplasmsCD8-Positive T-LymphocytesCatabolismCategoriesCell CycleCellsCharacteristicsClinicalClinical DataClinical TrialsCombined Modality TherapyDNA biosynthesisDataDevelopmentDiseaseDoseDrug IndustryEnvironmentEssential Amino AcidsFunctional disorderFutureGlioblastomaGliomaGoalsHumanImmuneImmune ToleranceImmune responseImmune systemImmunocompetentImmunosuppressionImmunotherapyIn SituInfectionInjectionsInterleukin-2KynurenineLaboratoriesLymphocyteMagnetic Resonance ImagingMalignant GliomaMalignant NeoplasmsMediatingMesocricetus auratusMetabolicModelingModificationMusNamesOncolyticOncolytic virusesOperative Surgical ProceduresPathway interactionsPatientsPhasePhase I Clinical TrialsPopulationPositioning AttributeProductionPublishingRecurrenceRegulatory T-LymphocyteSafetyShapesSiteSolid NeoplasmSpecimenSurvival RateT cell anergyT cell infiltrationT-Cell ActivationT-LymphocyteT-cell receptor repertoireTNFSF4 geneTestingTherapeuticTimeTranslatingTryptophanVaccinationViralVirotherapyVirusVirus DiseasesVirus Replicationadenoviral mediatedanti-canceranti-tumor immune responsecancer immunotherapycancer therapycytotoxicdeprivationeffective therapyfirst-in-humanimmune activationimmunogenic cell deathimmunotherapeutic virotherapyimprovedindoleamineinhibitorinterestmouse modelneoplastic cellnoveloncolysisoncolytic adenovirusoncolytic virotherapypatient subsetspermissivenesspre-clinicalpreventrecruitresponsestandard caretumortumor microenvironment
项目摘要
SUMMARY / ABSTRACT
With current treatment options, the five-year survival rate of patients with glioblastoma (GBM) is only 5%.
Oncolytic viruses are promising treatments against solid tumors, including malignant gliomas. In a phase I
clinical trial evaluating Delta-24-RGD, an oncolytic adenovirus characterized in our laboratory, 20% of recurrent
GBM patients receiving the virus achieved a durable response, surviving more than 3 years from the time of
treatment, suggesting the existence of a subgroup of patients who would respond to adenoviral treatments.
The clinical trial also showed that the efficacy of Delta-24-RGD was due to not only direct tumor cell oncolysis,
but also indirect activation of anti-tumor immune responses, a paradigm-shifting finding that radically
repositions virotherapy as a type of immunotherapy. Therefore, understanding the interplay between the
oncolytic effects of adenoviruses and the viral-mediated anti-glioma immune activation is critical in determining
how to increase the efficacy of these promising agents. Our group generated and preclinically characterized an
immune agonist-armed version of Delta-24-RGD, named Delta-24-RGDOX, which expresses the T-cell
activator OX40L, which will be soon translated to the clinical setting. In this project, we aim to amplify the effect
of Delta-24-RGDOX with the administration of inhibitors of the factors that maintain the immunosuppression
characteristic of gliomas. Because indoleamine-2,3-dioxgenase (IDO) expression increases significantly after
virus infection, we are particularly interested in developing strategies to downmodulate IDO during virotherapy.
The catabolism of tryptophan by IDO has important metabolic effects in glioma cells. In addition, the
metabolites of tryptophan, including kynurenine (Kyn), activate the aryl hydrocarbon receptor (AhR) that
induces Treg differentiation and CD8+ T-cell dysfunction. The central hypothesis of this study is that therapy
consisting of Delta-24-RGDOX in combination with IDO and AhR inhibitors will stimulate a cytotoxic immune
effect and inhibit the suppressive immune response against the tumor cells, thereby providing a potential
effective novel treatment for malignant gliomas. To test this hypothesis, we propose three aims: Specific Aim
1: Examine the activation of the IDO-Kyn-AhR pathway during the infection of gliomas with Delta-24-RGDOX
oncolytic adenovirus; Specific Aim 2: Identify the metabolic and immune modifications in the tumor
microenvironment produced by the inhibition of the IDO-Kyn-AhR pathway in gliomas treated with Delta-24-
RGDOX; and Specific Aim 3: Test the combination of Delta-24-RGDOX and IDO/AhR inhibitors in pre-
clinically relevant models of gliomas. This project is the next step in achieving our long-term goal of legitimizing
viro-immunotherapy as standard treatment for malignant gliomas.
总结/摘要
根据目前的治疗方案,胶质母细胞瘤(GBM)患者的五年生存率仅为5%。
溶瘤病毒是针对实体瘤(包括恶性神经胶质瘤)的有希望的治疗。在i期
一项临床试验评估Delta-24-RGD,一种在我们实验室表征的溶瘤腺病毒,20%的复发性
接受该病毒的GBM患者获得了持久的反应,从接种时起存活超过3年。
治疗,表明存在一个亚组的患者谁会响应腺病毒治疗。
临床试验还表明,Delta-24-RGD的功效不仅是由于直接的肿瘤细胞溶瘤作用,
而且还间接激活了抗肿瘤免疫反应,这是一个范式转变的发现,
将病毒疗法重新定位为一种免疫疗法。因此,了解
腺病毒的溶瘤作用和病毒介导的抗胶质瘤免疫激活是决定
如何提高这些有前途的药物的功效。我们的小组产生并临床前表征了
Delta-24-RGD的免疫激动剂武装版本,称为Delta-24-RGDOX,其表达T细胞
激活剂OX 40 L,将很快转化为临床环境。在这个项目中,我们的目标是放大效果
Delta-24-RGDOX与维持免疫抑制的因子的抑制剂的给药
神经胶质瘤的特征。由于吲哚胺-2,3-二氧合酶(IDO)表达在
因此,我们特别感兴趣的是开发在病毒治疗期间下调IDO的策略。
IDO对色氨酸的催化作用在胶质瘤细胞中具有重要的代谢作用。此外该
色氨酸的代谢物,包括犬尿氨酸(Kyn),激活芳基烃受体(AhR),
诱导Treg分化和CD 8 + T细胞功能障碍。这项研究的中心假设是,
由Delta-24-RGDOX与IDO和AhR抑制剂组合组成的组合物将刺激细胞毒性免疫
影响和抑制针对肿瘤细胞的抑制性免疫应答,从而提供潜在的
恶性胶质瘤有效新疗法。为了验证这一假设,我们提出了三个目标:
1:检查在用Delta-24-RGDOX感染神经胶质瘤期间IDO-Kyn-AhR途径的激活
溶瘤腺病毒;特定目标2:鉴定肿瘤中的代谢和免疫修饰
在用Delta-24-Kyn-AhR处理的胶质瘤中抑制IDO-Kyn-AhR通路产生的微环境。
具体目标3:在预处理中测试Δ-24-RGDOX和IDO/AhR抑制剂的组合。
神经胶质瘤的临床相关模型。这个项目是实现我们长期目标的下一步,
病毒免疫疗法作为恶性胶质瘤的标准治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Juan Fueyo其他文献
Juan Fueyo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Juan Fueyo', 18)}}的其他基金
Off-the-shelf Genetically Engineered Natural Killer Therapy for Glioblastoma
现成的胶质母细胞瘤基因工程自然杀伤疗法
- 批准号:
10474009 - 财政年份:2021
- 资助金额:
$ 36.32万 - 项目类别:
Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants
溶瘤腺病毒和免疫代谢佐剂治疗胶质瘤
- 批准号:
10330464 - 财政年份:2021
- 资助金额:
$ 36.32万 - 项目类别:
Tropism Enhanced Oncolytic Adenovirus for the Treatment of Brain Tumors
用于治疗脑肿瘤的趋向性增强溶瘤腺病毒
- 批准号:
9128419 - 财政年份:2008
- 资助金额:
$ 36.32万 - 项目类别:
相似海外基金
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 36.32万 - 项目类别:
Augmenting the Quality and Duration of the Immune Response with a Novel TLR2 Agonist-Aluminum Combination Adjuvant
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10499193 - 财政年份:2021
- 资助金额:
$ 36.32万 - 项目类别:
A Novel TLR5 Agonist-Based Adjuvant for Poliovirus Vaccine
一种基于 TLR5 激动剂的新型脊髓灰质炎病毒疫苗佐剂
- 批准号:
9305008 - 财政年份:2016
- 资助金额:
$ 36.32万 - 项目类别:
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine
血管生成拮抗剂加CD40-TLR激动剂佐剂组合疫苗
- 批准号:
8054408 - 财政年份:2010
- 资助金额:
$ 36.32万 - 项目类别:
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine
血管生成拮抗剂加CD40-TLR激动剂佐剂组合疫苗
- 批准号:
7909550 - 财政年份:2010
- 资助金额:
$ 36.32万 - 项目类别:
Malaria vaccines modified with TLR agonist adjuvant
TLR 激动剂佐剂修饰的疟疾疫苗
- 批准号:
8126073 - 财政年份:2010
- 资助金额:
$ 36.32万 - 项目类别:
Malaria vaccines modified with TLR agonist adjuvant
TLR 激动剂佐剂修饰的疟疾疫苗
- 批准号:
7899536 - 财政年份:2009
- 资助金额:
$ 36.32万 - 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
- 批准号:
7362543 - 财政年份:2007
- 资助金额:
$ 36.32万 - 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
- 批准号:
7502193 - 财政年份:2007
- 资助金额:
$ 36.32万 - 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
- 批准号:
7911043 - 财政年份:2007
- 资助金额:
$ 36.32万 - 项目类别: